31-07-2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Article content
LAVAL, Québec — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation ('VoxCell'), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials.
Article content
This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies.
Article content
'We're proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,'
Article content
said Steve Mason, Co-Chief Operating Officer at Altasciences.
Article content
'This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.'
Article content
VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies.
Article content
'Our mission has always been to make drug screening more human-relevant and predictive,'
Article content
said Karolina Valente, CEO of VoxCell BioInnovation.
Article content
'Altasciences shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.'
Article content
The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications.
Article content
This partnership represents a shared vision: to transform early-stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide.
Article content
About Altasciences
Article content
Altasciences
Article content
preclinical
Article content
and
Article content
clinical pharmacology
Article content
studies, including
Article content
formulation, manufacturing, and analytical services
Article content
. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include
Article content
,
Article content
clinical pharmacology and proof of concept
Article content
,
Article content
bioanalysis
Article content
, program management,
Article content
research support
Article content
, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit
Article content
.
Article content
About VoxCell BioInnovation
Article content
VoxCell BioInnovation
Article content
is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology research and drug development.
Article content
VoxCell develop 3D bioprinted vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for predictive, physiologically relevant research. Using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, they produce complex tissue models that mirror patient biopsy samples in structure and function.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content